@article{fdi:010055870,
  title = {{P}redictors of 5-year mortality in {HIV}-infected adults starting highly active antiretroviral therapy in {T}hailand},
  author = {{F}regonese, {F}. and {C}ollins, {I}. {J}. and {J}ourdain, {G}onzague and {L}e {C}oeur, {S}ophie and {C}ressey, {T}. {R}. and {N}go-{G}iang-{H}uong, {N}icole and {B}anchongkit, {S}. and {C}hutanunta, {A}. and {T}echapornroong, {M}. and {L}allemant, {M}arc},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjective: {T}o estimate the early and long-term mortalities and associated risk factors in adults receiving highly active antiretroviral therapy ({HAART}) in {T}hailand. {D}esign: {A} prospective observational cohort study. {M}ethods: {P}reviously untreated adults starting {HAART} in 2002-2009 were followed-up in 43 public hospitals. {K}aplan-{M}eier probability of survival was estimated up to 5 years of therapy. {F}actors associated with early (<= 6 months) and long-term (>6 months) mortalities were assessed using {C}ox regression analyses. {R}esults: {A} total of 1578 adults received {HAART} (74% women; median age, 33 years; {CD}4 cell count, 124/m{L}), with a median follow-up of 50 months (interquartile range, 41-66). {E}ighty-nine patients (6%) died (37 occurred <= 6 months and 52 occurred >6 months) and 183 (12%) were lost to follow-up. {P}robability of survival [95% confidence interval ({CI})] was 97.5% (96.7% to 98.2%) at 6 months, 96.6% (95.6% to 97.4%) at 1 year, and 93.5% (91.9% to 94.8%) at 5 years. {P}robability of being alive and on follow-up was 80.8% (78.5% to 82.8%) at 5 years. {E}arly mortality was associated with anemia [adjusted hazard ratio (a{HR}) 3.6, 95% {CI}: 1.7 to 7.5] and low {CD}4 count (a{HR} 1.6, 95% {CI}: 1.1 to 2.2 per 50 cells decrease) at treatment initiation. {L}ong-term mortality was associated with persistent anemia (a{HR} 4.9, 95% {CI}: 2.1 to 11.6), {CD}4 increase from baseline <50 cells per cubic millimeter (a{HR} 3.1, 95% {CI}: 1.6 to 5.7), and viral load >1000 copies per milliliter (a{HR} 2.8, 95% {CI}: 1.3 to 6.1) at 6 months of {HAART}; male gender; and calendar year of enrollment. {C}onclusions: {E}arly mortality was associated with anemia and severe immunosuppression at initiation of therapy. {L}ong-term mortality was associated with persistent anemia, {CD}4 count increase, and virological response at 6 months of therapy over baseline characteristics, highlighting the importance of laboratory monitoring.},
  keywords = {{HIV} ; antiretroviral therapy ; {HAART} ; survival ; {T}hailand},
  booktitle = {},
  journal = {{J}aids : {J}ournal of {A}cquired {I}mmune {D}eficiency {S}yndromes},
  volume = {60},
  numero = {1},
  pages = {91--98},
  ISSN = {1525-4135},
  year = {2012},
  DOI = {10.1097/{QAI}.0b013e31824bd33f},
  URL = {https://www.documentation.ird.fr/hor/fdi:010055870},
}